The Food and Drug Administration (FDA) is gearing up for a busy final week of June, with four significant target action dates on the horizon. Among the key decisions, the agency will consider a label expansion for a bispecific antibody and review an investigational gene therapy.
Merck is seeking approval for an expanded indication of their bispecific antibody, which has shown promise in treating additional medical conditions. Meanwhile, Verona Pharma awaits the FDA’s verdict on their novel therapeutic approach.
AbbVie is also in the spotlight, as the FDA evaluates their latest submission, which could potentially broaden treatment options for patients. Lastly, Rocket Pharmaceuticals is on the edge of their seats, anticipating the agency’s decision regarding their groundbreaking gene therapy.
As June comes to a close, the biotech industry eagerly awaits the FDA’s rulings, which could significantly impact patient care and shape the future of these innovative companies.